Association between melanoma and exposure to sex hormones in puberty: A possible window of susceptibility (Review)

Caroppo,Francesca; Cicogna,Giulia Tadiotto; Messina,Francesco; Alaibac,Mauro

doi:10.3892/mco.2021.2228

Association between melanoma and exposure to sex hormones in puberty: A possible window of susceptibility (Review)

Authors:
- Francesca Caroppo
- Giulia Tadiotto Cicogna
- Francesco Messina
- Mauro Alaibac
View Affiliations

Affiliations: Dermatology Unit, Department of Medicine, University of Padova, I‑35128 Padova, Italy
Published online on: February 8, 2021 https://doi.org/10.3892/mco.2021.2228
Article Number: 66

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The risk factors for melanoma in adolescents are similar to those in adults; however, it remains unclear whether these risk factors are also associated with melanoma in children. Epidemiological studies in the literature have reported a logarithmic increase in melanoma incidence after the age of 10 years. This may, in part, reflect the acute and chronic exposure to solar ultraviolet (UV) radiation during childhood. However, it appears unlikely that the cumulative exposure to UV radiation alone could explain such a sharp increase in melanoma incidence at the beginning of adolescence. It has been suggested that circulating sex hormones, the levels of which increase during puberty, may play a role in melanoma initiation and progression in predisposed individuals through binding to specific sex steroid receptors. The association between a longer cumulative exposure to sex hormones and the risk of melanoma may be supported by the reported epidemiological association between melanoma and several other sex hormone‑related types of cancer, such as breast and prostate cancer, in which the enhanced exposure to androgens and estrogens was found to be directly associated with pubertal onset. Therefore, determining the association between pubertal onset and melanoma development may improve the current understanding of melanoma pathophysiology.

View Figures

View References

1	Matthews NH, Li WQ, Qureshi AA, Weinstock MA and Cho E: Epidemiology of Melanoma. In: Cutaneous Melanoma: Etiology and Therapy [Internet]. Ward WH and Farma JM (eds). Codon Publications, Brisbane (AU), Dec 21, 2017.
2	Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, Wojcik K, Chapuis AG, Thompson JA, Madeleine MM and Gardner JM: Age-specific incidence of melanoma in the United States. JAMA Dermatol. 156:57–64. 2020.PubMed/NCBI View Article : Google Scholar
3	Eggen CAM, Durgaram VV, van Doorn R, Mooi WJ, Pardo LM, Pasmans SGMA and Hollestein LM: Incidence and relative survival of melanoma in children and adolescents in the Netherlands, 1989-2013. J Eur Acad Dermatol Venereol. 32:956–961. 2018.PubMed/NCBI View Article : Google Scholar
4	Whiteman DC, Valery P, McWhirter W and Green AC: Risk factors for childhood melanoma in Queensland, Australia. Int J cancer. 70:26–31. 1997.PubMed/NCBI View Article : Google Scholar
5	Dean PH, Bucevska M, Strahlendorf C and Verchere C: Pediatric melanoma: A 35-year population-based review. Plast Reconstr Surg Glob Open. 5(e1252)2017.PubMed/NCBI View Article : Google Scholar
6	Strouse JJ, Fears TR, Tucker MA and Wayne AS: Pediatric melanoma: Risk factor and survival analysis of the Surveillance, Epidemiology and End Results database. J Clin Oncol. 23:4735–4741. 2005.PubMed/NCBI View Article : Google Scholar
7	Farello G, Altieri C, Cutini M, Pozzobon G and Verrotti A: Review of the literature on current changes in the timing of pubertal development and the incomplete forms of early puberty. Front Pediatr. 7(147)2019.PubMed/NCBI View Article : Google Scholar
8	Berg P and Lindelof B: Differences in malignant melanoma between children and adolescents. A 35-year epidemiological study. Arch Dermatol. 133:295–297. 1997.PubMed/NCBI
9	Folkerd EJ and Dowsett M: Influence of sex hormones on cancer progression. J Clin Oncol. 28:4038–4044. 2010.PubMed/NCBI View Article : Google Scholar
10	Dika E, Patrizi A, Lambertini M, Manuelpillai N, Fiorentino M, Altimari A, Ferracin M, Lauriola M, Fabbri E, Campione E, et al: Estrogen receptors and melanoma: A review. Cells. 8(1463)2019.PubMed/NCBI View Article : Google Scholar
11	Marzagalli M, Marelli MM, Casati L, Fontana F, Moretti RM and Limonta P: Estrogen receptor β in melanoma: From molecular insights to potential clinical utility. Front Endocrinol (Lausanne). 7(40)2016.PubMed/NCBI View Article : Google Scholar
12	Schmidt AN, Nanney LB, Boyd AS, King LE and Ellis DL: Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 15:971–980. 2006.PubMed/NCBI View Article : Google Scholar
13	de Giorgi V, Gori A, Gandini S, Papi F, Grazzini M, Rossari S, Simoni A, Maio V and Massi D: Oestrogen receptor beta and melanoma: A comparative study. Br J Dermatol. 168:513–519. 2013.PubMed/NCBI View Article : Google Scholar
14	Donley GM, Liu WT, Pfeiffer RM, McDonald EC, Peters KO, Tucker MA and Cahoon EK: Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States. Br J Cancer. 120:754–760. 2019.PubMed/NCBI View Article : Google Scholar
15	Kvaskoff M, Bijon A, Mesrine S, Boutron-Ruault MC and Clavel-Chapelon F: Cutaneous melanoma and endogenous hormonal factors: A large French prospective study. Am J Epidemiol. 173:1192–1202. 2011.PubMed/NCBI View Article : Google Scholar
16	Holly EA, Cress RD and Ahn DK: Cutaneous melanoma in women: Ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev. 3:661–668. 1994.PubMed/NCBI
17	MacKie RM and Bray CA: Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer. 90:770–772. 2004.PubMed/NCBI View Article : Google Scholar
18	Caini S, Radice D, Tosti G, Spadola G, Cocorocchio E, Ferrucci PF, Testori A, Pennacchioli E, Fargnoli MC, Palli D, et al: Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy. J Eur Acad Dermatol Venereol. 30:1491–1496. 2016.PubMed/NCBI View Article : Google Scholar
19	Goggins W, Gao W and Tsao H: Association between female breast cancer and cutaneous melanoma. Int J Cancer. 111:792–794. 2004.PubMed/NCBI View Article : Google Scholar
20	Secreto G, Girombelli A and Krogh V: Androgen excess in breast cancer development: Implications for prevention and treatment. Endocr Relat Cancer. 26:R81–R94. 2019.PubMed/NCBI View Article : Google Scholar
21	Min M, Ghosh S, Tavernari D, Katarkar A, Clocchiatti A, Mazzeo L, Samarkina A, Epiney J, Yu YR, Ho PC, et al: Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. J Exp Med. 8(e20201137)2021.PubMed/NCBI View Article : Google Scholar
22	Goldenberg A, Jiang SI and Cohen PR: A possible association between melanoma and prostate cancer. Results from a case-control-study. Cancers (Basel). 7:670–678. 2015.PubMed/NCBI View Article : Google Scholar
23	Rampen FH and Mulder JH: Malignant melanoma: An androgen-dependent tumour? Lancet. 1:562–564. 1980.PubMed/NCBI View Article : Google Scholar
24	Slominski A, Tbin DJ, Shibahara S and Wortsman J: Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 84:1155–1228. 2004.PubMed/NCBI View Article : Google Scholar
25	Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, et al: Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med. 14(66)2016.PubMed/NCBI View Article : Google Scholar
26	Allil PA, Visconti MA, Castrucci AM and Isoldi MC: Photoperiod and testosterone modulate growth and melanogenesis of S91 murine melanoma. Med Chem. 4:100–105. 2008.PubMed/NCBI View Article : Google Scholar
27	Kim SH, Richardson M, Chinnakannu K, Bai VU, Menon M, Barrack ER and Reddy GP: Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem. 285:10472–10476. 2010.PubMed/NCBI View Article : Google Scholar
28	Zhou J, Richardson M, Reddy V, Menon M, Barrack ER, Reddy GP and Kim SH: Structural and functional association of androgen receptor with telomeres in prostate cancer cells. Aging. 5:3–17. 2013.PubMed/NCBI View Article : Google Scholar
29	Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo Q, et al: Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res. 71:6758–6763. 2011.PubMed/NCBI View Article : Google Scholar
30	Hsueh EC, Gupta RK, Lefor A, Reyzin G, Ye W and Morton DL: Androgen blockade enhances response to melanoma vaccine. J Surg Res. 110:393–398. 2003.PubMed/NCBI View Article : Google Scholar